| Literature DB >> 31908725 |
Li-Jun Jin1, Wei-Bin Chen2, Xiao-Yu Zhang1, Jie Bai1, Hao-Chen Zhao3, Zun-Yi Wang4.
Abstract
BACKGROUND: Accurate assessment of the prognosis after colorectal cancer surgery is of great significance in patients with colorectal cancer. However, there is no systematic analysis of factors affecting the prognosis of colorectal cancer currently. AIM: To systematically analyze the influence of clinical data and serological and histological indicators on the prognosis of patients with colorectal cancer, and to explore the indicators that can accurately assess the prognosis of patients with colorectal cancer.Entities:
Keywords: Colorectal cancer; Combination assessment; Influencing factors; Prognosis
Year: 2019 PMID: 31908725 PMCID: PMC6937433 DOI: 10.4251/wjgo.v11.i12.1206
Source DB: PubMed Journal: World J Gastrointest Oncol
Figure 1Survival curve analysis of patients with colorectal cancer (Kaplan-Meier). The poor prognosis rate was 22.82%.
Figure 2Endpoint events during postoperative follow-up of colorectal cancer patients. A: Colorectal cancer recurrence (arrow); B: Colorectal cancer liver metastasis (arrow); C: Colorectal cancer bone metastasis (arrow).
Comparison of indicators between the good prognosis group and poor prognosis group before treatment
| Age | 53.64 ± 15.38 | 60.47 ± 8.34 | 3.831 | 0.000 |
| Gender (Male/Female) | 143/131 | 43/38 | 0.020 | 0.887 |
| BMI (kg/m2) | 26.49 ± 5.34 | 25.39 ± 5.91 | 1.589 | 0.113 |
| Smoking [ | 74 (27.01%) | 24 (29.63%) | 0.215 | 0.643 |
| History of alcohol abuse [ | 39 (14.23%) | 13 (16.05%) | 0.165 | 0.685 |
| Family history [ | 46 (16.79%) | 20 (24.69%) | 2.580 | 0.108 |
| Tumor diameter (cm) | 2.08 ± 1.47 | 5.69 ± 2.54 | 16.125 | 0.000 |
| Tumor location | ||||
| Ascending colon [ | 39 | 13 | 3.139 | 0.535 |
| Transverse colon [ | 14 | 7 | ||
| Lower colon [ | 25 | 10 | ||
| Sigmoid colon [ | 84 | 22 | ||
| Rectum [ | 112 | 29 | ||
| Tumor histology type | ||||
| Adenocarcinoma | 177 | 53 | 0.019 | 0.890 |
| Mucinous adenocarcinoma and signet ring cell carcinoma | 97 | 28 | ||
| TNM stage | ||||
| I | 10 (3.65%) | 6 (7.41%) | 29.292 | 0.000 |
| II | 213 (77.74%) | 38 (46.91%) | ||
| III | 30 (10.95%) | 24 (29.63%) | ||
| IV | 21 (7.66%) | 13 (16.05%) | ||
| Dukes stage | ||||
| A | 17 (6.20%) | 1 (1.23%) | 0.062 | |
| B | 177 (64.60%) | 48 (59.26%) | ||
| C | 80 (29.20%) | 32 (39.51%) | ||
| PCNA | ||||
| 1 | 98 | 4 | 114.291 | 0.000 |
| 2 | 122 | 11 | ||
| 3 | 45 | 43 | ||
| 4 | 9 | 23 | ||
| P53 | ||||
| - | 34 | 11 | 4.908 | 0.297 |
| + | 64 | 14 | ||
| ++ | 61 | 17 | ||
| +++ | 78 | 23 | ||
| ++++ | 37 | 19 | ||
| GPS | ||||
| 0 | 233 (85.04%) | 9 (11.11%) | 157.579 | 0.000 |
| 1 | 24 (8.76%) | 40 (49.38%) | ||
| 2 | 17 (6.20%) | 32 (39.51%) | ||
| C-reactive protein (mg/L) | 2.73 ± 0.64 | 21.83 ± 16.34 | 19.364 | 0.000 |
| Albumin (g/L) | 42.43 ± 7.93 | 33.74 ± 6.21 | 9.071 | 0.000 |
| WBC count (9 × 103/mm3) | 5.89 ± 1.98 | 8.53 ± 2.83 | 9.481 | 0.000 |
| Platelet count (9 × 104/mm3) | 237.43 ± 103.28 | 247.23 ± 116.39 | 0.728 | 0.467 |
| NLR | 2.68 ± 1.73 | 4.53 ± 3.29 | 6.699 | 0.000 |
| CAR | 0.089 ± 0.017 | 0.175 ± 0.092 | 14.693 | 0.000 |
| D-dimer (μg/mL) | 0.553 ± 0.207 | 0.943 ± 0.375 | 13.117 | 0.000 |
| Fibrinogen (g/L) | 3.121 ± 1.542 | 3.524 ± 1.053 | 2.204 | 0.028 |
| CEA (ng/mL) | 3.34 ± 1.82 | 6.13 ± 2.36 | 11.281 | 0.000 |
| CA199 (U/mL) | 186.82 ± 139.74 | 635.24 ± 284.38 | 15.067 | 0.000 |
BMI: Body mass index; TNM: Tumor-node-metastasis; PCNA: Proliferating cell nuclear antigen; GPS: Glasgow prognostic score; WBC: White blood cell; NLR: Neutrophil-lymphocyte ratio; CAR: C-reactive protein/albumin ratio; CEA: Carcinoembryonic antigen; CA199: Carbohydrate antigen 199.
COX regression analysis of influence factors on the prognosis of colorectal cancer
| Age | 0.241 | 0.223 | 1.328 | 0.154 | 1.273 | 0.822 | 1.971 |
| Tumor diameter | 0.160 | 0.315 | 1.142 | 0.328 | 1.173 | 0.633 | 2.175 |
| TNM Stage | 1.762 | 0.442 | 7.364 | 0.000 | 5.824 | 2.449 | 13.850 |
| PCNA | 1.534 | 0.382 | 6.338 | 0.000 | 4.635 | 2.192 | 9.800 |
| GPS | 2.238 | 0.448 | 8.927 | 0.000 | 9.377 | 3.897 | 22.564 |
| C-reactive protein | 0.454 | 0.355 | 2.773 | 0.058 | 1.574 | 0.785 | 3.156 |
| Albumin | -0.129 | 0.371 | 2.538 | 0.105 | 0.879 | 0.425 | 1.819 |
| WBC count | 0.149 | 0.433 | 1.292 | 0.183 | 1.161 | 0.497 | 2.713 |
| NLR | 0.816 | 0.233 | 6.792 | 0.000 | 2.261 | 1.432 | 3.570 |
| CAR | 2.678 | 0.341 | 9.338 | 0.000 | 14.552 | 7.459 | 28.391 |
| D-dimer | 2.498 | 0.636 | 8.923 | 0.000 | 12.153 | 3.494 | 42.272 |
| Fibrinogen | 0.603 | 0.386 | 0.751 | 0.625 | 1.827 | 0.857 | 3.893 |
| CEA | 1.342 | 0.492 | 6.877 | 0.000 | 3.827 | 1.459 | 10.038 |
| CA199 | 0.226 | 0.553 | 1.149 | 0.322 | 1.253 | 0.424 | 3.704 |
TNM: Tumor-node-metastasis; PCNA: Proliferating cell nuclear antigen; GPS: Glasgow prognostic score; WBC: White blood cell; NLR: Neutrophil-lymphocyte ratio; CAR: C-reactive protein/albumin ratio; CEA: Carcinoembryonic antigen; CA199: Carbohydrate antigen 199.
Receiver-operating characteristic (ROC) curve analysis of potential indicators for predicting the prognosis of colorectal cancer
| TNM Stage | 0.613 | 0.560-0.663 | 2 | 45.68 | 81.39 |
| PCNA | 0.837 | 0.794-0.874 | 2 | 81.48 | 80.29 |
| GPS | 0.872 | 0.832-0.905 | 1 | 88.89 | 85.04 |
| NLR | 0.925 | 0.860-0.966 | 0.206 | 94.12 | 80.25 |
| CAR | 0.743 | 0.695-0.788 | 4.81 | 45.68 | 94.53 |
| D-dimer | 0.879 | 0.841-0.911 | 0.795 (μg/mL) | 58.02 | 100 |
| CEA | 0.801 | 0.755-0.841 | 3.891 (ng/mL) | 76.54 | 64.60 |
TNM: Tumor-node-metastasis; PCNA: Proliferating cell nuclear antigen; GPS: Glasgow prognostic score; NLR: Neutrophil-lymphocyte ratio; CAR: C-reactive protein/albumin ratio; CEA: Carcinoembryonic antigen.
Figure 3Receiver operating characteristic curve analysis of potential indicators for predicting the prognosis of colorectal cancer.
Figure 4Receiver operating characteristic curve analysis of the combination assessment for predicting the prognosis of colorectal cancer.